Agenus Inc. (NASDAQ:AGEN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have been given an average rating of “Hold” by the six analysts that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Several research firms have commented on AGEN. StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. B. Riley cut their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright cut their price objective on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 12th.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in shares of Agenus by 81.3% during the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 84,477 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after acquiring an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after acquiring an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 123,058 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of Agenus during the second quarter worth about $1,921,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Trading Up 3.3 %

Shares of AGEN opened at $3.49 on Thursday. The firm has a market capitalization of $81.88 million, a P/E ratio of -0.31 and a beta of 1.39. The stock’s fifty day simple moving average is $4.30 and its 200 day simple moving average is $8.20. Agenus has a twelve month low of $2.50 and a twelve month high of $19.69.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.